SILO · Silo Pharma, Inc.
The latest filing states the doubt was alleviated.
“The positive working capital serves to mitigate the conditions that historically raised substantial doubt about the Company's ability to continue as a going concern. The Company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.”View the 10-Q filed May 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-12-15 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,500 |
| 2025-12-15 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,500 |
| 2025-11-21 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
1,000 |
| 2025-11-20 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
1,000 |
| 2025-11-19 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
4,500 |
| 2025-11-18 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
7,500 |
| 2025-05-27 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions at prices ranging from $0.42 to $0.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
10,000 |
| 2025-05-23 | Munoz Kevin |
Director |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Options (right to buy)
|
50,000 |
| 2025-05-23 | Linsley Wayne |
Director |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Options (right to buy)
|
50,000 |
| 2025-05-23 | Pavell Jeff |
Director |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Options (right to buy)
|
50,000 |
| 2025-05-23 | Ryweck Daniel E. |
Chief Financial Officer |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Options (right to buy)
|
50,000 |
| 2025-05-23 | Weisblum Eric |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Options (right to buy)
|
200,000 |
| 2024-12-13 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,500 |
| 2024-11-22 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,500 |
| 2024-11-20 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
2,500 |
| 2024-06-12 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
4,438 |
| 2024-06-11 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
562 |
| 2024-04-05 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.05. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
400 |
| 2024-04-04 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.96 to $1.97. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
600 |
| 2024-04-01 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $1.93. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
1,100 |
| 2024-03-28 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.91 to $1.95. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
3,408 |
| 2023-12-20 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.63. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
200 |
| 2023-12-19 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
500 |
| 2023-12-15 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.52. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
900 |
| 2023-12-14 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
200 |
| 2023-12-07 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.34 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
324 |
| 2023-12-06 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
76 |
| 2023-12-05 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
600 |
| 2023-11-30 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.55. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
1,000 |
| 2023-11-29 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.56 to $1.57. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
1,000 |
| 2023-11-27 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
250 |
| 2023-11-22 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.70. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
400 |
| 2023-11-21 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
300 |
| 2023-11-20 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
4,050 |
| 2023-11-17 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.60. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
1,800 |
| 2023-11-16 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.46. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
1,100 |
| 2023-05-26 | Ryweck Daniel E. |
Chief Financial Officer |
Buy↑
|
Common Stock
|
1,000 |
| 2023-05-18 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at $2.104 and $2.109. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
500 |
| 2023-05-17 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.000 to $2.0899. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
2,500 |
| 2022-12-20 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
130 |
| 2022-12-19 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.713. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
200 |
| 2022-12-14 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
263 |
| 2022-12-13 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.992 to $3.20. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
487 |
| 2022-09-27 | Pavell Jeff |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-06-17 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1302 to $0.11. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
13,080 |
| 2021-12-29 | Linsley Wayne |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (Direct)
This Form 4/A deletes the second Non-Qualified Stock Option for 171,233 shares erroneously reported in the original Form 4 filed on January 3, 2022. The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. Vests over the course of one year from grant with 100% vesting a year from the date of grant. |
Non-Qualified Stock Option
|
171,233 |
| 2021-12-29 | Munoz Kevin |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (Direct)
The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. Vests over the course of one year from grant with 100% vesting a year from the date of grant. |
Non-Qualified Stock Option
|
171,233 |
| 2021-12-13 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.131 to $0.1455. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
|
17,500 |
| 2021-12-10 | Weisblum Eric |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
5,000 |
| 2020-10-01 | Munoz Kevin |
Director |
Other↑
|
No Securities Owned
|
0 |